Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.


Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities. The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation. Complementing the expansion has been the hiring of rich talent globally resulting in nearly 3x growth of the team size.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “The focus of innovator companies on diversifying their supply chains bodes well for Indian CROs-CDMOs like ours. This expansion in our DMPK capabilities demonstrates our commitment and appetite for large, complex programs and our readiness to offer world-class DMPK services at scale.”   

The current expansion strengthens the company’s ongoing commitment to its clients for providing high-quality data and industry-leading turnaround time for absorption, distribution, metabolism, and excretion (ADME) screening and pharmacokinetics (PK) studies. 

Key highlights: 

  • In vitro ADME: A centralized lab design where assays are performed using automation in consolidated lab space to increase speed, throughput and quality.
  • In vivo Pharmacokinetics: Expanded space for animal holding; procedure and surgical rooms for supporting rodent PK studies; formulation screening and mass balance/tissue distribution studies.
  • Bioanalytical: State-of-the-art infrastructure for supporting bioanalysis of samples at higher sensitivity and faster turnaround time; In vitro and In vivo Metabolite identification (Met ID) studies enabled.
  • Toxicology: Space expansion with dedicated necropsy rooms, and safety hoods to perform non-GLP in vitro safety and in vivo tox studies supported by immunohistochemistry and toxicokinetic (TK) analyses. Additional efforts on alternative in vitro approaches to animal models are underway. 
  • Ion-channel physiology and safety pharmacology: Dedicated lab for manual patch-clamp setup for supporting cardiotoxicity profiling and for any ion-channel-based research.

Sauri Gudlavalleti, Chief Operating Officer said, “The latest expansion of DMPK capabilities augments our integrated drug discovery (IDD) offerings. We have now emerged as a one-stop provider of DMPK services with high-level automation and the latest technologies. This coupled with our world-class MedChem, Biology, DMPK and Toxicology under one roof, we are better prepared than ever to offer end-to-end IDD services to global clients.”

The DMPK team at Sai Life Sciences has experience of working with over 80 clients across the USA and UK supporting diverse drug discovery programs for various drug modalities- small molecules, PROTACs, molecular glues and peptides.  Even as Sai Life Sciences announces expansion of its DMPK capabilities, the expansion of its Vivarium for supporting animal efficacy, PK-PD and safety studies is underway which is expected to be ready by the end of this quarter. Sai Life Sciences also has plans to invest in niche areas such as peptides, oligos and large molecules to strengthen its discovery capabilities.

Share article

More News


Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more


Sai Life Sciences strengthens discovery leadership

Sai Life Sciences, a leading global contract research, development, and manufacturing organization, announces the addition of two seasoned professionals to its leadership team. Dr Atul Tiwari joins as Vice President – Discovery Strategy & Business, while Dr Santosh Kulkarni takes on the role of Vice President – Medicinal Chemistry. Their wealth of experience promises to […]
Read more


Sai Life Sciences wins Gold in Brandon Hall Group’s Excellence in Technology Awards

Sai Life Sciences won Gold in Brandon Hall Group’s Excellence in Technology Awards in the ‘Best Advance in Content Authoring Technology’ category. Sai Life Sciences was recognized for the use of UL Create Tool, an easy-to-use, cloud-based authoring tool from UL Solutions, for making the learning process seamless and effective for all. The company utilized […]
Read more


Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more



Sai Life Sciences joins Science Based Targets initiative (SBTi), commits to fight climate change with Science

To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, it has committed to set near-term company-wide emission reductions in line with […]
Read more